Structural Heart Disease

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.

Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

Nearly half of patients with acute coronary syndrome in a single-center analysis exhibited iron deficiency, with anemia linked to a greater impact on mortality.

Greg Duck, PA-C shared insights from his CAPP 2024 presentation on tailoring medical management and effective treatment of methamphetamine-induced cardiomyopathy.

Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

Birgit Vogel, MD discusses racial inequities and geographic variations in peripheral artery disease care in the United States.

Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.

As advancements in valvular technology progress, Nguyen highlights the need for long-term data and multidisciplinary collaboration to improve patient outcomes.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.